Hormonal
Bariatric surgery, particularly Roux-en-Y gastric bypass and biliopancreatic diversion, induces Type 2 Diabetes remission in a majority of patients through mechanisms exceeding simple caloric restriction, including hormonal changes (GLP-1, PYY) and altered gut microbiome.
For eligible patients with obesity and T2DM, bariatric surgery is the most potent intervention for achieving remission, often outperforming medication. It works by altering gut hormones that improve insulin sensitivity, not just by making the stomach smaller. Consultation with a bariatric specialist is required to assess eligibility based on BMI and diabetes duration.
Metabolic surgery results in changes in the hormonal environment, such as increased levels of glucagon-likepeptide-1 (GLP-1) and the YY peptide... Several studies also claimed that higher levels of serum bile acids are associated with the stimulation of GLP-1 secretion. These combined effects can improve pancreatic β-cell function and lead to increased insulin release and sensitivity
Why this rating
Supported by multiple RCTs and long-term cohort studies cited in the review.
Source
Remission as an Emerging Therapeutic Target in Type 2 Diabetes in the Era of New Glucose-Lowering Agents: Benefits, Challenges, and Treatment Approaches
Dimitra Vasdeki et al. · Nutrients · 2022
DOI 10.3390/nu14224801
More from this paper
- Significant weight loss (typically >15 kg or >15% of baseline weight) induced by dietary interventions (Very Low-Calorie Diets or Low-Carbohydrate Diets) is the strongest predictor of Type 2 Diabetes remission, regardless of the specific macronutrient composition.Good
- Novel glucose-lowering agents, specifically GLP-1 receptor agonists (semaglutide) and dual GIP/GLP-1 agonists (tirzepatide), induce significant weight loss and glycemic improvement, with tirzepatide showing remission rates of 66-81% in clinical trials.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →